Claims for Patent: 10,071,139

Summary for Patent: 10,071,139

Title:	Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
Abstract:	Methods and compositions for reducing one or more of triglyceride levels, total cholesterol levels and LDL cholesterol levels in a subject are provided. The methods include administering a fragment of ANGPTL8 to a subject having or at risk of developing elevated triglyceride levels, elevated total cholesterol levels and/or elevated LDL cholesterol levels.
Inventor(s):	Liu; Zhonghao (San Bruno, CA), Ding; Xunshan (San Bruno, CA)
Assignee:	NGM Biopharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	15/318,937
Patent Claims:	1. A method of reducing triglyceride levels in a subject having or at risk of developing elevated triglyceride levels, the method comprising: administering to the subject a polypeptide comprising a contiguous amino acid sequence having at least 95% sequence identity to the amino acid sequence of amino acids 80-198 of full-length angiopoietin-like protein 8 (ANGPTL8) (SEQ ID NO. 1), wherein the polypeptide lacks the amino acids 21-70 of full-length ANGPTL8 (SEQ ID NO: 1), and wherein the polypeptide is administered in an amount effective to reduce the triglyceride levels in the subject. 2. The method of claim 1, wherein the contiguous amino acid sequence has at least 97% sequence identity to the amino acid sequence of amino acids 80-198 of full-length ANGPTL8 (SEQ ID NO. 1). 3. The method of claim 1, wherein the contiguous amino acid sequence has at least 99% sequence identity to the amino acid sequence of amino acids 80-198 of full-length ANGPTL8 (SEQ ID NO. 1). 4. The method of claim 1, wherein the contiguous amino acid sequence has the amino acid sequence of amino acids 80-198 of full-length ANGPTL8 (SEQ ID NO. 1). 5. The method of claim 4, wherein the subject has elevated triglyceride levels. 6. The method of claim 5, wherein the subject is overweight or obese. 7. The method of claim 1, wherein a heterologous polypeptide is conjugated to the N-terminus or C-terminus of the polypeptide. 8. The method of claim 7, wherein the heterologous polypeptide is albumin or human serum albumin. 9. The method of claim 7, wherein the heterologous polypeptide is conjugated to the polypeptide via a cleavable linker sequence or a non-cleavable linker sequence. 10. The method of claim 7, wherein the heterologous polypeptide is an immunoglobulin Fc. 11. The method of claim 1, wherein the administering reduces triglyceride levels by at least 5% compared to triglyceride levels in the subject prior to the administering of the polypeptide. 12. The method of claim 1, wherein the administering reduces triglyceride levels by at least 10% compared to triglyceride levels in the subject prior to the administering of the polypeptide. 13. The method of claim 1, wherein the administering reduces triglyceride levels by at least 20% compared to triglyceride levels in the subject prior to the administering of the polypeptide. 14. The method of claim 1, wherein the subject is overweight or obese. 15. The method of claim 1, wherein the subject has diabetes. 16. The method of claim 1, wherein the subject has hypothyroidism. 17. The method of claim 1, wherein the subject has elevated triglyceride levels. 18. The method of claim 17, wherein an immunoglobulin Fc is conjugated to the N-terminus or C-terminus of the polypeptide. 19. The method of claim 5, wherein an immunoglobulin Fc is conjugated to the N-terminus or C-terminus of the polypeptide. 20. The method of claim 6, wherein an immunoglobulin Fc is conjugated to the N-terminus or C-terminus of the polypeptide.

Details for Patent 10,071,139

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	October 21, 1942	10,071,139	2034-10-03
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	March 03, 1954	10,071,139	2034-10-03
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	July 23, 1976	10,071,139	2034-10-03
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	August 15, 1978	10,071,139	2034-10-03
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	November 29, 2022	10,071,139	2034-10-03
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	February 17, 1995	10,071,139	2034-10-03